eurofins | Biomnis

Oncomedics
CliniSciences Group

The Oncogramme®

Towards personalised medicine for all cancer patients

Chances of response to first-line chemotherapy treatment of a patient with a metastatic colorectal cancer



Without Oncogramme®



With Oncogramme®



CE IVD

Oncogramme for Metastatic colorectal concer performed by Eurofins Biomnis in Europe

What is the Oncogramme® ?

The **Oncogramme® predicts the anti-cancer activity of existing combination of treatments** by testing them directly on a patient's operated tumor. Their efficacy is evaluated on a sample of this tumor *ex vivo*, using an approach comparable to that of the antibiogram.

How can treatments be personalised?

Every cancer patient requires special attention, ideally involving an individualised treatment. The majority of patients today need chemotherapy to fight cancer effectively, but no test or biomarker can predict their effectiveness. Targeted therapies are a first line of defense against the disease, but not all patients are eligible for them.


Based on a model similar to the antibiogram, **Oncomedics has developed and marketed an innovative functional assay**. Such assays are an **important tool to help in the choice of chemotherapy**. A recent review showed that functional tests had **an efficiency of 80%[3] .**

Since 2016, patients with **stage IV colorectal cancer** can benefit from the Oncogramme® CE/IVD (FOLFIRI, FOLFOX, 5FU+Folinic Acid): a unique solution to personalise chemotherapy.

In December 2019, Oncomedics received a favourable decision from the French National Authority for Health **(HAS)** via the "Forfait Innovation" for the derogatory reimbursement of the Oncogramme®[3].

The Oncogramme® will soon be optimised for other cancers such as **breast cancer and ovarian cancer**, to improve treatment by tailoring it to each patient.


eurofins | Biomnis
Oncomedics
CliniSciences Group



eurofins | Biomnis


Oncomedics
CliniSciences Group

The Oncogramme® for metastatic colorectal cancer: First indication available as CE/IVD marked diagnostic test



FOLFIRINOX: oxaliplatin, irinotecan, 5-Fluorouracil + Folinic acid
FOLFIRI: irinotecan, 5-Fluorouracil + Folinic acid
FOLFOX: oxaliplatin, 5-Fluorouracil + Folinic acid

Oncomedics's results with the Oncogramme® in metastatic colorectal cancer suggest an increased chance of response to first-line treatments: 84%[1] compared to 21% (5- FU alone) to 48% (FOLFOX) at best in the literature[4] for the main consensus chemotherapy treatments.



1. Bounaix Morand du Puch et al. J Transl Med. 2016 Jan 12;14:1.
2. Bounaix Morand du Puch et al.,Theranostics. 2021 Sep 21;11(19):9538-9556.
3. https://hassante.fr/upload/docs/application/pdf/202001/ac_2019_0064_forfait_innov_oncogramme_avec_modif_cd_2019_12_18_vd.pdf
4. Pfeiffer et al. Onco Targets Ther. 2009; 2:17-27.

eurofins | Biomnis
17/19 avenue Tony Garnier BP 7322 - 69357 LYON Cedex 07 - FRANCE
+33 4 72 80 23 85
www.eurofins-biomnis.com
international@biomnis.eurofinseu.com

Oncomedics CliniSciences Group
5 Rue de Gémini, 87280 Limoges - France
+33 5 55 33 85 25
www.oncomedics.com
info@oncomedics.com